CAPLIN POINT LABORATORIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,295 INR | -0.08% |
|
-2.71% | -4.51% |
| 05-06 | Caplin Point Laboratories Gets Colombian Drug Regulator's Approval for Soft Gel Capsules Unit in India | MT |
| 04-16 | Caplin Point Arm Gets US FDA Final Nod for Ofloxacin Ophthalmic Solution | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.51% | 1.18B | C | ||
| +20.20% | 43.74B | B- | ||
| +21.76% | 22.26B | B+ | ||
| +16.41% | 14.9B | - | ||
| +10.57% | 13.39B | B+ | ||
| +45.66% | 12.12B | B | ||
| -9.76% | 6.92B | B+ | ||
| -0.05% | 6.79B | - | - | |
| -8.87% | 5.73B | - | - | |
| +12.41% | 5.47B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CAPLIPOINT Stock
- Ratings Caplin Point Laboratories Limited
